Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction

2003154 citationsJournal Articlebronze Open Access

Authors

James E. Tcheng · Eli Lilly (United States)

David E. Kandzari · Adventist HealthCare

Cindy L. Grines · University of Bergamo

David A. Cox · Moses H Cone Memorial Hospital

Mark B. Effron · Adventist HealthCare

Eulogio Garcı́a · Beaumont Hospital, Royal Oak

John J. Griffin ·

Abstract

Adjunctive abciximab treatment during primary percutaneous coronary intervention significantly enhanced 30-day event-free survival, predominantly by reducing ischemia-driven TVR. Abciximab treatment did not affect the composite end point at 1 year, reflecting a lack of effect on restenosis.

Topics & Keywords

Acute Myocardial Infarction Research Coronary Interventions and Diagnostics Cardiac Imaging and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 108, Issue 11, pp. 1316-1323

DOI: 10.1161/01.cir.0000087601.45803.86

Field-Weighted Citation Impact: 11.14